maybe the environment / sentiment from big pharma has changed. or something has come into play for benitec that
has enabled a change in strategy. i'm cool with flexible
strategy if the cards are changing.
say they do land a modest deal for a pre clinical that had some useful upfront, if that deal were with a big pharma, then i think the market will value benitec not just on that
deal alone, but also provide some re-evaluation based on it's other prospects. i don't want to speculate how much that re-evaulation could be, but bigger players taking a first look at benitec's other prospective therapy areas will be in for quite a surprise...
- Forums
- ASX - By Stock
- BLT
- $1b deal here were come
$1b deal here were come, page-14
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online